Faculty Articles

Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder

Publication Title

P&T (Pharmacy & Therapeutics)

Volume

41

Issue

7

Publication Date / Copyright Date

7-1-2016

First Page

418

Last Page

422

Publisher

MediMedia

Abstract

Mental health disorders affect approximately one in five adults in a given year. In the United States, approximately 1% of adults live with schizophrenia, and nearly 7% of adults have experienced at least one major depressive episode.1

The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), defines schizophrenia as having two or more of the following symptoms for a substantial amount of time during a one-month period that leads to a significant decrease in level of functioning. The symptoms include grossly disorganized or catatonic behavior, negative symptoms (i.e., avolition or reduced emotional expression), and at least one of these symptoms: delusions, hallucinations, or disorganized speech.2

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

brexpiprazole (Rexulti), depression, schizophrenia, United States

Link to Full Text
Peer Reviewed

Find in your library

Share

 
COinS